Review Article
Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
Table 1
Anti-angiogenic agents trialled in high-grade glioma and their respective targets.
| Antibody Therapies | Major Molecular Targets | Bevacizumab | Free VEGF-A | IMC-3G3 | PDGFR alpha | Ramucirumab | VEGFR-2 | Nimotuzumab | EGFR | AMG-102 | Hepatocyte Growth Factor | VEGF-trap | Decoy receptor for VEGF |
| Tyrosine Kinase Inhibitors | | Cediranib | VEGFR/PDGFR/c-Kit | Sorafenib | VEGFR/PDGFR/c-Kit/Raf | Sunitinib | VEGFR/PDGFR | AE788 | EGFR/VEGFR | Erlotinib | EGFR | Imatinib | PDGFR/Bcr-abl/c-Kit | Dasatanib | Src kinases |
| Signal Pathway Inhibitors | | Enzastaurin | Protein Kinase C | Rapamycin/Temsirolimus | mTOR | Tipifarnib | Ras |
| Other Agents | | Thalidomide/Lenalidomide | NO/TNF alpha/IL-6 | Celecoxib | Endostatin | Cilengitide | Integrins and | 2-methoxyestradiol | HIF1 | Prinomastat | MMPs 2,9,13 and 14 | SAHA(Vorinostat) | Histone deacetylase |
|
|